Next-Generation Antibody Therapeutics Market Growth, Share, Demand Analysis of Key Players

The size of the next-generation antibody therapeutics market was about $5,620 million in 2021, which will reach about $15,309 million by 2030, at a growth rate of 12%.

Oncology Category Leading the Way

Oncology had the larger share, of about 80%, in the past, and it will demonstrate a growth rate of approximately 13%, in the near future. This is due to the increasing occurrence of breast cancer, prostate cancer, colorectal cancer, lung cancer, and brain cancer.

Antibody–Drug Conjugate Demand Will Grow Fastest

ADCs had the largest revenue share in 2021, and their revenue contribution will grow at a rate of around 12%. This is because of the high requirement for antibody-based cancer therapy, in part, due to the increasing occurrence of breast cancer and technical progressions in oncologic therapy.

Moreover, recently, there has been an increase in the occurrence of multiple myeloma globally, driving the requirement for ADCs. Furthermore, the initiatives by federal agencies for supporting these therapeutic candidates will boost the proceeds for biopharma and pharma firms.

• North America has the highest revenue, of approximately $2.5 billion, because of the increase in the funds for R&D by private and government institutions. This is essentially due to the rising incidence of chronic diseases, which create a high demand for novel solutions.
• The U.S., followed by Canada, will dominate the industry in the future, driven by the growing per capita healthcare spending.
• The presence of key players, increase in the approvals for next-gen antibody therapeutics, and existence of notable research facilities drive the growth of the industry.

ADCs To Revolutionize Cancer Treatment?

The ADC technology is becoming popular, as the cytotoxic nature of antibodies is potentially beneficial in chemotherapy. This property is articulated and its effectiveness and specificity are controlled by these conjugates. Because of the high competence delivered by ADCs, pharma and biotech companies are progressively concentrating on their development.